Regulatory Insights

  1. Understanding Subjective Outcome Measures In HAP Studies 4/28/2026

    Understanding how a participant "feels" is essential for drug safety. Explore how subjective measures and specialized training provide the data needed to evaluate human abuse potential.

  2. Statistical Analysis In Human Abuse Potential Studies 4/28/2026

    Gain clarity on the rigorous statistical frameworks and Emax endpoint analyses required to evaluate drug abuse potential and satisfy complex regulatory safety standards.

  3. Why RWD Strategy Can't Wait With Price, Value And Evidence Pressures Everywhere 4/27/2026

    Overcome pricing pressures and reimbursement delays by integrating real-world evidence early in development to align clinical outcomes with payer demands and accelerate patient access.

  4. From Bench To Breakthrough: How Custom Kitting Fuels Precision Trials 4/27/2026

    Reduce trial variability and ensure protocol compliance with standardized custom kitting that transforms complex sample collection into a streamlined, strategic advantage for clinical success.

  5. Managing Opportunities And Risks In Generative AI Use For Clinical Research 4/15/2026

    Explore how to bridge the gap between generative AI potential and clinical regulations through smarter oversight, adversarial agents, and a workforce prepared for human-AI collaboration.

  6. The Next Era Of eCOA Is AI 4/15/2026

    Discover how AI is moving beyond the hype to streamline clinical study builds. Explore practical ways to automate protocol digitization and UAT scripts while preparing for future patient tools.

  7. Build Systems That Scale With Every Stage Of Growth 4/15/2026

    Learn how to synchronize finance and R&D with a scalable operational framework. Automate manual steps and strengthen compliance to ensure your infrastructure evolves as fast as your science.

  8. Understanding When AI Models Need To Be Validated For Regulated Industries 4/15/2026

    Focus AI validation on decision impact rather than just algorithms. Aligning assurance with intended use and human oversight ensures safety while enabling faster, more compliant adoption.

  9. Countdown To Compliance: Navigating New UK Requirements 4/15/2026

    Senior experts from the HRA, the ISRCTN Registry (BMC), and Quotient Sciences discuss the implications of New UK regulations for clinical trial registration for sponsors and how to maintain compliance.

  10. Futureproofing Post-Approval Compliance 4/15/2026

    In the post-approval stage, a synergistic operating model brings PV and regulatory functions under one umbrella: a single governance structure with shared decision cycles, templates, and evidence.